Literature DB >> 26795965

Dysbiosis of the fecal microbiota in the TNBS-induced Crohn's disease mouse model.

Qing He1, Xiaoping Li2, Chuan Liu2,3, Lili Su2,3, Zhongkui Xia2,3, Xin Li2, Ying Li1, Lingling Li4, Ting Yan4, Qiang Feng5,6, Liang Xiao7,8.   

Abstract

Crohn's disease (CD) is characterized by chronic transmural inflammation. The symptom of the mice model induced by 2,4,6-trinitrobenzenesulfonic acid (TNBS) is closed to human under CD condition, so this kind of animal is widely used in the related researches. Although the dysbiosis of the fecal microbiota has been proved to play an important role in the patients with CD, the composition of the gastrointestinal microbiota in the mouse model under disease condition is still unclear. In the current study, male 7-week BALB/c mice were anesthetized and intrarectal administrated by ethanol (ET group), TNBS in ethanol (TN group), and phosphate buffered saline (PBS) (CK group) as control. The symptoms of individuals under the CD condition were observed, and the changes of the bacterial taxonomic structure and functional composition were revealed by next-generation sequencing (NGS) 16S sequencing. The BALB/c mice in TN group demonstrated CD-like symptoms and the damages in the intestinal tract. The NGS 16S results exhibited that the diversity and microbial composition under CD condition are significantly different with those in ET group. The KEGG Orthology (KO) profile were generated from PICRUSt, and function modules such as methanogenesis (M00347) and microcin C transport system (M00349) were found enriched in the individuals in the TN group. This study proved that mouse model induced by TNBS could develop the similar symptom to CD patient, and we firstly showed the significant intestinal microbe changes on both taxonomic structure and functional composition in this mouse model.

Entities:  

Keywords:  Crohn’s disease; Fecal microbiome; Inflammatory bowel disease; Mouse model; TNBS-induced

Mesh:

Substances:

Year:  2016        PMID: 26795965     DOI: 10.1007/s00253-015-7205-x

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  16 in total

1.  Repeated Oral Exposure to N ε-Carboxymethyllysine, a Maillard Reaction Product, Alleviates Gut Microbiota Dysbiosis in Colitic Mice.

Authors:  Nesreen ALJahdali; Pascale Gadonna-Widehem; Carine Delayre-Orthez; David Marier; Benjamin Garnier; Franck Carbonero; Pauline M Anton
Journal:  Dig Dis Sci       Date:  2017-09-30       Impact factor: 3.199

2.  Genetic and transcriptional analysis of human host response to healthy gut microbiota.

Authors:  Allison L Richards; Michael B Burns; Adnan Alazizi; Luis B Barreiro; Roger Pique-Regi; Ran Blekhman; Francesca Luca
Journal:  mSystems       Date:  2016-08-30       Impact factor: 6.496

3.  Modulation of Gut Microbiome Composition and Function in Experimental Colitis Treated with Sulfasalazine.

Authors:  Haihui Zheng; Mingyi Chen; Yuan Li; Yuanyuan Wang; Lin Wei; Ziqiong Liao; Mengxia Wang; Fangli Ma; Qiongfeng Liao; Zhiyong Xie
Journal:  Front Microbiol       Date:  2017-09-07       Impact factor: 5.640

4.  Biogeography and environmental conditions shape bacteriophage-bacteria networks across the human microbiome.

Authors:  Geoffrey D Hannigan; Melissa B Duhaime; Danai Koutra; Patrick D Schloss
Journal:  PLoS Comput Biol       Date:  2018-04-18       Impact factor: 4.475

5.  Antibiotic-mediated bacteriome depletion in ApcMin/+ mice is associated with reduction in mucus-producing goblet cells and increased colorectal cancer progression.

Authors:  Kamaljeet Kaur; Arpit Saxena; Irina Debnath; Jacqueline L O'Brien; Nadim J Ajami; Thomas A Auchtung; Joseph F Petrosino; Alexander-Jacques Sougiannis; Sarah Depaep; Alexander Chumanevich; Phani M Gummadidala; Mayomi H Omebeyinje; Sourav Banerjee; Ioulia Chatzistamou; Paramita Chakraborty; Raja Fayad; Franklin G Berger; James A Carson; Anindya Chanda
Journal:  Cancer Med       Date:  2018-04-06       Impact factor: 4.452

6.  Therapeutic effects of lentinan on inflammatory bowel disease and colitis-associated cancer.

Authors:  Yanrong Liu; Jianmin Zhao; Yali Zhao; Shumin Zong; Yixuan Tian; Shuang Chen; Meng Li; Huijuan Liu; Qiang Zhang; Xueshuang Jing; Bo Sun; Hongzhi Wang; Tao Sun; Cheng Yang
Journal:  J Cell Mol Med       Date:  2018-11-24       Impact factor: 5.310

7.  Self-tunable engineered yeast probiotics for the treatment of inflammatory bowel disease.

Authors:  Benjamin M Scott; Cristina Gutiérrez-Vázquez; Liliana M Sanmarco; Jessica A da Silva Pereira; Zhaorong Li; Agustín Plasencia; Patrick Hewson; Laura M Cox; Madelynn O'Brien; Steven K Chen; Pedro M Moraes-Vieira; Belinda S W Chang; Sergio G Peisajovich; Francisco J Quintana
Journal:  Nat Med       Date:  2021-06-28       Impact factor: 53.440

Review 8.  Dysbiosis of gut microbiota in promoting the development of colorectal cancer.

Authors:  Shaomin Zou; Lekun Fang; Mong-Hong Lee
Journal:  Gastroenterol Rep (Oxf)       Date:  2017-10-11

9.  A novel affordable reagent for room temperature storage and transport of fecal samples for metagenomic analyses.

Authors:  Mo Han; Lilan Hao; Yuxiang Lin; Fang Li; Jian Wang; Huanming Yang; Liang Xiao; Karsten Kristiansen; Huijue Jia; Junhua Li
Journal:  Microbiome       Date:  2018-02-27       Impact factor: 14.650

Review 10.  Preclinical Study in Vivo for New Pharmacological Approaches in Inflammatory Bowel Disease: A Systematic Review of Chronic Model of TNBS-Induced Colitis.

Authors:  Inês Silva; Rui Pinto; Vanessa Mateus
Journal:  J Clin Med       Date:  2019-10-01       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.